Roche's Perjeta Works in Early-Stage Breast Cancer

Trial data on Swiss drugmaker Roche's breast cancer treatment Perjeta supported a faster approval of the drug for use in early stages of the disease, reviewers for the U.S. Food and Drug Administration said on Tuesday. Roche is seeking approval for Perjeta as a neoadjuvant, or initial, treatment for early stage breast cancer patients whose cancer cells contain increased amounts of the HER2 protein. A neoadjuvant treatment is given in the beginning to shrink a tumor before the main treatment.

Help employers find you! Check out all the jobs and post your resume.